CMS’ proposed changes to the Medicare Shared Savings Program (MSSP) doesn’t represent a major shift in policy stance toward accountable care organizations (ACOs), said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.
CMS’ proposed changes to the Medicare Shared Savings Program (MSSP) doesn’t represent a major shift in policy stance toward accountable care organizations (ACOs), said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.
Transcript
If the proposed CMS changes to the MSSP are expected to make fewer ACOs participate, do you think the proposal will affect the ACO movement?
I wouldn’t say that this is a major change in policy with regard to ACOs. The current administration has clearly accepted the concept of ACOs, they’re clearly trying to promote them in a way.
I would say that Andy Slavitt, who was the CMS administrator under [President] Obama, said something to the effect of “yeah, there should be a time limit and if you’re not successful within a reasonable time limit, then you should go. Because it’s not going to work out for you.” So, I think that’s kind of a hard-eyed business look at this. But I don’t think this is a major change in policy.
They’re going to have to do other things to either strongly promote ACOs or strongly discourage them. I think one of the things that would promote ACOs or promote movement toward a more sensible approach to delivery, in general, would be to follow some of MedPAC [Medicare Payment Advisory Commission]’s suggestions with regard to fixing MIPS [Merit-based Incentive Payment System] and fixing MACRA [Medicare Access and CHIP Reauthorization Act], which is a problem all by itself.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More